2024
Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society–USA Panel
Gandhi R, Landovitz R, Sax P, Smith D, Springer S, Günthard H, Thompson M, Bedimo R, Benson C, Buchbinder S, Crabtree-Ramirez B, del Rio C, Eaton E, Eron J, Hoy J, Lehmann C, Molina J, Jacobsen D, Saag M. Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society–USA Panel. JAMA 2024, 333 PMID: 39616604, DOI: 10.1001/jama.2024.24543.Peer-Reviewed Original ResearchAntiretroviral drugsHIV preventionSubstance use disordersLong-acting injectable therapyManagement of HIV infectionIntegrase strand transfer inhibitorsNucleotide reverse transcriptase inhibitorsStrand transfer inhibitorsSexually transmitted infectionsPeer-reviewed scientific conferencesDaily oral medicationReverse transcriptase inhibitorsLong-acting medicationsManagement of substance use disordersPrevention of HIVCardiovascular disease preventionTreating substance use disordersVirological failureAntiretroviral therapyHIV acquisitionHIV infectionHIV exposureInjection therapyDaily therapyLaboratory monitoringConsiderations when prescribing opioid agonist therapies for people living with HIV
Tarfa A, Lier A, Shenoi S, Springer S. Considerations when prescribing opioid agonist therapies for people living with HIV. Expert Review Of Clinical Pharmacology 2024, 17: 549-564. PMID: 38946101, PMCID: PMC11299801, DOI: 10.1080/17512433.2024.2375448.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidAnti-HIV AgentsBuprenorphineDelayed-Action PreparationsDelivery of Health CareDrug InteractionsHealth Services AccessibilityHIV InfectionsHumansMethadoneNaltrexoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPre-Exposure ProphylaxisUnited StatesConceptsOpioid agonist therapyOpioid use disorderAntiretroviral therapyAgonist therapyDiagnosed OUDOpioid use disorder managementUse disorderTreatment of opioid use disorderExtended-release naltrexonePotential drug interactionsOpioid use disorder treatmentPrescribed opioid agonist therapyLong-acting formulationPre-exposure prophylaxisOUD outcomesImprove HIV preventionIntersection of HIVOpioid antagonistHIV outcomesHIV epidemicOpioidHIVOpioid use disorder servicesPWHHIV prevention
2022
Study protocol of a randomized controlled trial comparing two linkage models for HIV prevention and treatment in justice-involved persons
Springer SA, Nijhawan AE, Knight K, Kuo I, Di Paola A, Schlossberg E, Frank CA, Sanchez M, Pankow J, Proffitt RP, Lehman W, Pulitzer Z, Thompson K, Violette S, Harding KK. Study protocol of a randomized controlled trial comparing two linkage models for HIV prevention and treatment in justice-involved persons. BMC Infectious Diseases 2022, 22: 380. PMID: 35428213, PMCID: PMC9013109, DOI: 10.1186/s12879-022-07354-x.Peer-Reviewed Original ResearchConceptsJustice-involved individualsAntiretroviral treatmentHIV preventionUse disordersStudy participantsStimulant useSubstance use disorder servicesCommunity-based HIVPost-release interventionsPrimary implementation outcomeHIV viral loadPre-exposure prophylaxisOpioid use disorderTreatment of HIVHIV risk behaviorsRisk of HIVSubstance use disordersHigh-risk communitiesHybrid type 1Justice-involved personsHCV testingLinkage interventionHIV careSecondary outcomesART adherence
2020
Preventing HIV outbreaks among people who inject drugs in the United States: plus ça change, plus ça même chose.
Strathdee SA, Kuo I, El-Bassel N, Hodder S, Smith LR, Springer SA. Preventing HIV outbreaks among people who inject drugs in the United States: plus ça change, plus ça même chose. AIDS 2020, 34: 1997-2005. PMID: 32826391, PMCID: PMC7606503, DOI: 10.1097/qad.0000000000002673.Peer-Reviewed Original ResearchConceptsHIV outbreakRecent HIV outbreaksEpidemiology of HIVEvidence-based interventionsOpioid disordersHIV infectionTreatment cascadeEvidence-based responsesHIV epidemicOpioid epidemicHIV preventionPrescription opiatesHIVPWIDSynthetic opioidsDrugsPublic healthInfectionPreventionHigher proportionUnited StatesEpidemicOutbreakEditorial reviewRelentless cycle
2017
Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine
Marcus R, Makarenko I, Mazhnaya A, Zelenev A, Polonsky M, Madden L, Filippovych S, Dvoriak S, Springer SA, Altice FL. Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine. Drug And Alcohol Dependence 2017, 179: 213-219. PMID: 28806638, PMCID: PMC5599372, DOI: 10.1016/j.drugalcdep.2017.07.010.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid use disorderExtended-release naltrexoneXR-NTXHIV preventionIndependent correlatesPatient preferencesUse disordersShort-term injectorsPatient-centered treatmentAgonist therapyPharmacological therapyHIV incidenceTreatment optionsPWIDTreatment entryAddiction treatmentPreventionNaltrexoneShort durationTherapyNegative attitudesDisordersNew optionsTreatment
2015
Drug Treatment as HIV Prevention Among Women and Girls Who Inject Drugs From a Global Perspective
Springer SA, Larney S, Alam-mehrjerdi Z, Altice FL, Metzger D, Shoptaw S. Drug Treatment as HIV Prevention Among Women and Girls Who Inject Drugs From a Global Perspective. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 69: s155-s161. PMID: 25978482, PMCID: PMC4443704, DOI: 10.1097/qai.0000000000000637.Peer-Reviewed Original ResearchConceptsMedication-assisted therapyDrug treatmentAntiretroviral therapyHIV transmission riskNew HIV infectionsHarm reduction servicesSubstance use disordersPoor treatment accessImplementation of interventionsOpioid useHIV infectionEvidence-based practiceHIV preventionOpioid addictionTreatment accessUse disordersReduction servicesSexual riskTransmission riskTherapyWomenTreatmentDrugsImpressive lackSignificant reduction
2011
Advances in the prevention of heterosexual transmission of HIV/AIDS among women in the United States
Chen N, Meyer J, Springer S. Advances in the prevention of heterosexual transmission of HIV/AIDS among women in the United States. Infectious Disease Reports 2011, 3: 6. DOI: 10.4081/idr.2011.2362.Peer-Reviewed Original ResearchHIV/AIDSHeterosexual transmissionVaginal pre-exposure prophylaxisSpecific high-risk groupsPre-exposure prophylaxisHigh-risk groupNon-Hispanic blacksHistory of incarcerationHIV transmissionBiologic susceptibilityVaginal microbicidesHIV preventionFemale condomNew infectionsU.S. womenMale partnersWomenIntimate partner violenceImportance of advocacyAIDSCondomsVulnerability of womenPreventionInterventionPartner violenceAdvances in the prevention of heterosexual transmission of HIV/AIDS among women in the United States
Chen NE, Meyer JP, Springer SA. Advances in the prevention of heterosexual transmission of HIV/AIDS among women in the United States. Infectious Disease Reports 2011, 3: e6. PMID: 23745166, PMCID: PMC3671603, DOI: 10.4081/idr.2011.e6.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsHIV/AIDSHeterosexual transmissionVaginal pre-exposure prophylaxisSpecific high-risk groupsPre-exposure prophylaxisHigh-risk groupNon-Hispanic blacksHistory of incarcerationHIV transmissionBiologic susceptibilityVaginal microbicidesHIV preventionFemale condomNew infectionsU.S. womenMale partnersWomenIntimate partner violenceImportance of advocacyAIDSCondomsVulnerability of womenPreventionInterventionPartner violence